Merck Scraps Covid-19 Vaccine Candidates The two shots generated comparatively weak immune responses in early-stage studies
By Jared S. Hopkins
Merck said it would now focus on advancing two experimental Covid-19 drugs.
Merck & Co. said Monday that it is halting development of its two experimental Covid-19 vaccines, after early clinical-trial data showed the shots generated disappointing immune responses against the virus.
Early-stage studies of the vaccines indicated they produced inferior immune responses in subjects given the shots compared with people who survived Covid-19 or took authorized Covid-19 vaccines, the company said.
